# Case Report: Diverse pediatric phenotypes of RELA frameshift variants: comparison of two cases

**Authors:** Ling Hou, Lu Yin, Chengguang Zhao, Yue Du

PMC · DOI: 10.3389/fimmu.2026.1756745 · Frontiers in Immunology · 2026-02-18

## TL;DR

Two children with RELA gene variants showed different autoinflammatory symptoms, highlighting the variable effects of these mutations in pediatric patients.

## Contribution

This case report identifies diverse clinical manifestations of RELA frameshift variants in children and suggests the importance of RELA screening in unexplained autoinflammatory cases.

## Key findings

- Patient 1 with a RELA variant showed Behçet’s disease-like symptoms and responded to colchicine and steroids.
- Patient 2 with a different RELA variant had systemic inflammation and hearing loss, and improved with adalimumab.
- In vitro assays showed altered NF-κB signaling and gene expression in patient-derived cells.

## Abstract

Variants in RELA (which encodes the p65 subunit of NF-κB) can cause a monogenic autoinflammatory disease with clinical manifestations that range from mucocutaneous lesions (Behçet’s disease-like) to systemic inflammation. However, the diversity of the phenotype and its penetrance are uncertain.

Patient 1 (p.Asp465Thrfs14) presented with classic Behçet’s disease-like symptoms of oral and genital ulcers, fever, and elevated inflammatory markers. Colchicine (0.25 mg once daily) with low-dose glucocorticoids led to remission. Exploratory in vitro assays using murine fibroblasts indicated increased TNF-α–induced apoptosis associated with the RELA variant. Patient 2 (p.Glu495Serfs6) had no mucosal lesions but experienced recurrent high fever, hyperferritinemia, uveitis/scleritis, and progressive bilateral sensorineural hearing loss. Because IL-1 blockers were not available, we administered adalimumab as a steroid-sparing treatment. Defervescence was achieved within 6 months of adalimumab therapy, with stabilization of inflammatory markers and hearing thresholds during the entire 9-month follow-up. PBMCs from Patient 2 and the carrier mother that were stimulated by LPS had decreased induction of two genes targeted by NF-κB (BCL2A1, TRAF1), and the proband (but not the mother) had markedly increased IL-6 secretion.

C-terminal truncations in the transcriptional activation domain of RELA lead to haploinsufficiency and an inflammatory phenotype that depends on the cell type and stimulus. RELA screening should be considered in the evaluation of children with unexplained autoinflammatory presentation, even in the absence of mucosal ulceration.

## Linked entities

- **Genes:** RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970], BCL2A1 (BCL2 related protein A1) [NCBI Gene 597], TRAF1 (TNF receptor associated factor 1) [NCBI Gene 7185]
- **Proteins:** RELA (RELA proto-oncogene, NF-kB subunit), TNF (tumor necrosis factor), IL6 (interleukin 6), NFKB1 (nuclear factor kappa B subunit 1)
- **Chemicals:** colchicine (PubChem CID 2833)
- **Diseases:** Behçet’s disease (MONDO:0007191), uveitis (MONDO:0020283), scleritis (MONDO:0001718), sensorineural hearing loss (MONDO:0010576)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, BCL2A1 (BCL2 related protein A1) [NCBI Gene 597] {aka ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, OTULIN (OTU deubiquitinase with linear linkage specificity) [NCBI Gene 90268] {aka AIPDS, AIPDSA, FAM105B, GUM, IMD107}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, IKBKG (inhibitor of nuclear factor kappa B kinase regulatory subunit gamma) [NCBI Gene 8517] {aka AMCBX1, EDAID1, FIP-3, FIP3, Fip3p, IKK-gamma}, TRAF1 (TNF receptor associated factor 1) [NCBI Gene 7185] {aka EBI6, MGC:10353}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, ERAP1 (endoplasmic reticulum aminopeptidase 1) [NCBI Gene 51752] {aka A-LAP, ALAP, APPILS, ARTS-1, ARTS1, ERAAP}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL23R (interleukin 23 receptor) [NCBI Gene 149233] {aka PSORS7}
- **Diseases:** autoinflammation (MESH:D056660), immune dysregulation (OMIM:614878), SNHL (MESH:D006319), fever (MESH:D005334), primary immunodeficiencies (MESH:D000081207), neuromyelitis optica (MESH:D009471), aphthae (MESH:D013281), monogenic disorder (MESH:D009358), systemic lupus erythematosus (MESH:D008180), infectious (MESH:D003141), irritable bowel disease (MESH:D043183), BD (MESH:D001528), lymphadenopathy (MESH:D008206), inborn errors (MESH:D008661), autoimmune (MESH:D001327), cutaneous lesions (MESH:D009059), DN (MESH:D064726), IBD (MESH:D015212), aphthous scars (MESH:D002921), uveitis (MESH:D014605), type I interferonopathy (MESH:D006969), associated (MESH:D018886), hyperferritinemia (MESH:D000085583), vulvar ulcers (MESH:D014845), infection (MESH:D007239), ALPS (MESH:C565232), immune disorders (MESH:D007154), autoimmune lymphoproliferative syndrome (MESH:D056735), arthralgia (MESH:D018771), cytotoxicity (MESH:D064420), -dominant (MESH:C566739), neutrophilic leukocytosis (MESH:D007964), mucocutaneous ulcers (MESH:D014456), scleritis (MESH:D015423), inflammatory (MESH:D007249), mucocutaneous lesions (MESH:D007897), oral and genital ulcers (MESH:D019226)
- **Chemicals:** Colchicine (MESH:D003078), tazobactam (MESH:D000078142), steroid (MESH:D013256), adalimumab (MESH:D000068879), LPS (MESH:D008070), ceftriaxone (MESH:D002443), canakinumab (MESH:C541220)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Legionella sp. H (species) [taxon 66966], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.1483delG, p.Asp465Thrfs14, p.Glu495Serfs6, c.1392delA
- **Cell lines:** L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957222/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957222/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957222/full.md

---
Source: https://tomesphere.com/paper/PMC12957222